A post by @FirstSquawk on X.
Moderna Q3 Earnings:
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Moderna reported third-quarter revenue of $1.31 billion, far exceeding the $888.1 million consensus estimate, and earnings per share of 38 cents versus an expected loss of $1.09 per share. R&D spending came in at $583 million, below the $750 million estimate, while total operating expenses of $1.18 billion also beat expectations of $1.37 billion. Cash and cash equivalents stood at $1.20 billion, short of the $1.37 billion estimate. The company guided full-year capital expenditure to $200 million, narrowing its prior $200 million to $300 million range and below the $244.1 million consensus. The results matter as a sign of sharper cost discipline and better-than-expected top-line performance, and investors will watch whether the lower spending trajectory is sustained and how cash reserves trend next quarter.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
A linked name opens that asset's sentiment page.